| Filed On | Filing |
|---|---|
| 19 Oct 2026 | ARS |
| 19 Oct 2026 |
Proxy statement: annual meeting on November 9, 2026
CEO pay $1.1M, down 32% · say-on-pay vote |
| 15 Oct 2026 |
Form 3: Farrow Jeffrey S, Director
Holds 0 shares of No securities are beneficially owned |
| 14 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee |
| 07 Oct 2026 | PRE 14A |
| 02 Oct 2026 | D |
| 28 Sep 2026 |
Form 3: Love Ted W, Director
Holds 19,260 shares of Common Stock |
| 28 Sep 2026 |
Form 3: Lehrer-Graiwer Joshua, President & COO
Holds 21,548 shares of Common Stock |
| 17 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of September 17, 2026, by and among Lisata Therapeutics, Inc., a Delaware corporation (“Parent”), Mariner Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiar... |
| 26 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 04 Aug 2026 | 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more |
| 28 Jul 2026 | SC TO-T/A |
| 24 Jul 2026 | 8-K: Termination of a Material Definitive Agreement; Other Events |
| 21 Jul 2026 | SC 14D9/A |
| 17 Jul 2026 | SC 14D9/A |
| 17 Jul 2026 | SC TO-T/A |
| 17 Jul 2026 | 8-K: Entry into a Material Definitive Agreement |
| 13 Jul 2026 | SC 14D9/A |
| 10 Jul 2026 | SCHEDULE TO-T/A |
Loading...
